The Epidemiological Modelling of Major Depressive Disorder: Application for the Global Burden of Disease Study 2010
نویسندگان
چکیده
BACKGROUND Although the detrimental impact of major depressive disorder (MDD) at the individual level has been described, its global epidemiology remains unclear given limitations in the data. Here we present the modelled epidemiological profile of MDD dealing with heterogeneity in the data, enforcing internal consistency between epidemiological parameters and making estimates for world regions with no empirical data. These estimates were used to quantify the burden of MDD for the Global Burden of Disease Study 2010 (GBD 2010). METHOD Analyses drew on data from our existing literature review of the epidemiology of MDD. DisMod-MR, the latest version of the generic disease modelling system redesigned as a Bayesian meta-regression tool, derived prevalence by age, year and sex for 21 regions. Prior epidemiological knowledge, study- and country-level covariates adjusted sub-optimal raw data. RESULTS There were over 298 million cases of MDD globally at any point in time in 2010, with the highest proportion of cases occurring between 25 and 34 years. Global point prevalence was very similar across time (4.4% (95% uncertainty: 4.2-4.7%) in 1990, 4.4% (4.1-4.7%) in 2005 and 2010), but higher in females (5.5% (5.0-6.0%) compared to males (3.2% (3.0-3.6%) in 2010. Regions in conflict had higher prevalence than those with no conflict. The annual incidence of an episode of MDD followed a similar age and regional pattern to prevalence but was about one and a half times higher, consistent with an average duration of 37.7 weeks. CONCLUSION We were able to integrate available data, including those from high quality surveys and sub-optimal studies, into a model adjusting for known methodological sources of heterogeneity. We were also able to estimate the epidemiology of MDD in regions with no available data. This informed GBD 2010 and the public health field, with a clearer understanding of the global distribution of MDD.
منابع مشابه
Burden of Mental Disorders: A Study of the Middle East Countries for the Period 2000- 2017
Background: Mental disorders, as the most important global health challenge these days, have created many concerns for health systems, health professionals and policy makers and are a major contributor to the growth of health complications and disabilities worldwide. The present study was designed and conducted to describe the status of the illness burden of mental disorders in the Middle Easte...
متن کاملBurden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010
BACKGROUND Depressive disorders were a leading cause of burden in the Global Burden of Disease (GBD) 1990 and 2000 studies. Here, we analyze the burden of depressive disorders in GBD 2010 and present severity proportions, burden by country, region, age, sex, and year, as well as burden of depressive disorders as a risk factor for suicide and ischemic heart disease. METHODS AND FINDINGS Burden...
متن کاملCorrelation of HbA1c and Major Depressive Disorder in Type 2 Diabetic Patients
OBJECTIVE: To evaluate the relation between major depressions and glucose control index in type 2 diabetes mellitus. MATERIALS AND METHODS: One- hundred thirty four patients with type 2 diabetes were enrolled in this study. Hamilton Rating Scale for Depression (HAM-D) and HbA1c were measured in patients. Linear mixed-model analysis was applied to determine the relation between HbA1c levels and...
متن کاملApplications of the epidemiological modelling outputs for targeted mental health planning in conflict-affected populations: the Syria case-study
BACKGROUND Epidemiological models are frequently utilised to ascertain disease prevalence in a population; however, these estimates can have wider practical applications for informing targeted scale-up and optimisation of mental health services. We explore potential applications for a conflict-affected population, Syria. METHODS We use prevalence estimates of major depression and post-traumat...
متن کاملVortioxetine versus placebo for treatment of major depressive disorder
Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics. Materials and methods: A comprehensive literature search (PubMed, the Cochrane libr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 8 شماره
صفحات -
تاریخ انتشار 2013